As peptide science continues to evolve, products such as the KLOW blend may contribute to deeper scientific understanding and generate valuable insights for future investigations
Innovent has 10 products in the market, including TYVYT (Sintilimab Injection), BYVASDA (Bevacizumab Injection), SULINNO (Adalimumab Injection), HALPRYZA (Rituximab Injection), Pemazyre (Pemigatinib Oral Inhibitor), olverembatinib, Cyramza (Ramucirumab Injection), Retsevmo (Selpercatinib Capsules ), FUCASO (Equecabtagene Autoleucel Injection) and SINTBILO (Tafolecimab Injection)
It is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: References Mechanism of Action 1-2 Bremelanotide, a MCR agonist, non-selectively works on several receptor subtypes MC1R-MC5R in the central nervous system
For the broader pipeline context around these compounds, see our investigational peptide drugs for diabetes and obesity reviews 2019-2026 guide